MS-33

N/A

Report date: 2023/01/13 17:13:04
NME

Base Information

Drug NameMS-33
Drug Alias NameMS-33
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionWD repeat-containing protein 5 inhibitorsProteolysis
TargetsWD repeat-containing protein 5
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount Sinai
China Registration ClassN/A

Develop Information

Active CompaniesIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A